PCRX
Pacira BioSciences, Inc.
OpenVolumeMkt capP/EEPSDiv yield
Day – 52-wk –
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Pacira BioSciences, Inc.
Expected move
InputsNext report
Last report
Largest filed tie
13F top-10 QoQ
Top fund weight
Last report1 of 8 at or beyond impliedshaded = implied▲▼ = realized× = |realized| ÷ implied
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida.
No thesis.
Annual filing, covered
10-K parsed · Feb 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
Annual filing, covered
10-K parsed · Feb 26 '26
Supply-chain ties, covered
Disclosed · both directions
Fund holders, covered
N-PORT holdings
13F holdings, covered
13F quarter · Jun 30 '26
Management, not covered
Not covered · DEF 14A, 8-K 5.02
Company IR feed, not covered
News via newswires & EDGAR
Products, patents, hiring, not covered
Not covered
−9.96%
vs ±9.3% implied · ×1.08
shaded = implied · ▲▼ = realized
Pacira BioSciences, Inc.
36.39
0.00 · 0.00%
Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; Pacira BioSciences, Inc.'s closest co-mover is outside that code.
Closest co-movers · 501d
MCBMetropolitan Bank Holding×0.22r 0.25Same SIC code · 6
Same SEC industry code: ELI Lilly & Co, Johnson & Johnson, AbbVie Inc. and 3 more; Pacira BioSciences, Inc.'s closest co-mover is outside that code.
Closest co-movers · 501d
MCBMetropolitan Bank Holding×0.22r 0.25Tall tick = annual report · Source: EDGAR
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $170.1M | 15.33% | −0.44% |
| Doma Perpetual | $70.5M | 6.35% | 0.00% |
| Vanguard Portfolioindex-like | $61.0M | 5.50% | −3.80% |
| Dimensional | $53.4M | 4.81% | +2.07% |
| State Streetindex-like | $52.3M | 4.71% | +7.31% |
| Manager | Value | % base | |
|---|---|---|---|
| BlackRockindex-like | $170.1M | 15.33% | −0.44% |
| Doma Perpetual | $70.5M | 6.35% | 0.00% |
| Vanguard Portfolioindex-like | $61.0M | 5.50% | −3.80% |
| Dimensional | $53.4M | 4.81% | +2.07% |
| State Streetindex-like | $52.3M | 4.71% | +7.31% |
Bull1
Bear2
Expected move
Inputsspot 36.39exp Nov 20ATM strike 37.5ATM straddle 2.07IV 28%